These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 36645718)
21. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Georgiadis A; Durham JN; Keefer LA; Bartlett BR; Zielonka M; Murphy D; White JR; Lu S; Verner EL; Ruan F; Riley D; Anders RA; Gedvilaite E; Angiuoli S; Jones S; Velculescu VE; Le DT; Diaz LA; Sausen M Clin Cancer Res; 2019 Dec; 25(23):7024-7034. PubMed ID: 31506389 [TBL] [Abstract][Full Text] [Related]
22. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191 [TBL] [Abstract][Full Text] [Related]
24. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898 [TBL] [Abstract][Full Text] [Related]
25. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
26. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745 [TBL] [Abstract][Full Text] [Related]
27. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374 [TBL] [Abstract][Full Text] [Related]
28. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Scarpa A Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588 [TBL] [Abstract][Full Text] [Related]
30. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Lu M; Zhang P; Zhang Y; Li Z; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Wang X; Zhou J; Peng Z; Wang W; Feng H; Wu H; Yao S; Shen L Clin Cancer Res; 2020 May; 26(10):2337-2345. PubMed ID: 32086343 [TBL] [Abstract][Full Text] [Related]
31. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
32. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
34. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related]
36. Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway. Yang Y; Gu X; Li Z; Zheng C; Wang Z; Zhou M; Chen Z; Li M; Li D; Xiang J Aging (Albany NY); 2021 Oct; 13(19):23262-23283. PubMed ID: 34642262 [TBL] [Abstract][Full Text] [Related]
37. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients. Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937 [TBL] [Abstract][Full Text] [Related]